# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in ...
Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and c...
Amgen and AstraZeneca reveal Phase 2a results for Tezspire in severe COPD, showing a 17% reduction in exacerbations, with notab...
Late-breaking results from the Phase IIa COURSE trial provide insight into TEZSPIRE's impact on COPD exacerbations in patie...
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled ...
FDA approves Amgen's Imdelltra for treating ES-SCLC, based on response rate and DoR in clinical studies. Approval may depen...